Spice Alex J, Aw Rochelle, Bracewell Daniel G, Polizzi Karen M
Department of Chemical Engineering, Imperial College London, London, United Kingdom.
The Imperial College Centre for Synthetic Biology Imperial College London, London, United Kingdom.
Front Bioeng Biotechnol. 2020 Feb 14;8:72. doi: 10.3389/fbioe.2020.00072. eCollection 2020.
Virus-like particles (VLPs) are supramolecular protein assemblies with the potential for unique and exciting applications in synthetic biology and medicine. Despite the attention VLPs have gained thus far, considerable limitations still persist in their production. Poorly scalable manufacturing technologies and inconsistent product architectures continue to restrict the full potential of VLPs. Cell-free protein synthesis (CFPS) offers an alternative approach to VLP production and has already proven to be successful, albeit using extracts from a limited number of organisms. Using a recently developed based CFPS system, we have demonstrated the production of the model Hepatitis B core antigen VLP as a proof-of-concept. The VLPs produced in the CFPS system were found to have comparable characteristics to those previously produced and . Additionally, we have developed a facile and rapid synthesis, assembly and purification methodology that could be applied as a rapid prototyping platform for vaccine development or synthetic biology applications. Overall the CFPS methodology allows far greater throughput, which will expedite the screening of optimal assembly conditions for more robust and stable VLPs. This approach could therefore support the characterization of larger sample sets to improve vaccine development efficiency.
病毒样颗粒(VLPs)是超分子蛋白质聚集体,在合成生物学和医学领域具有独特且令人兴奋的应用潜力。尽管VLPs迄今为止已受到关注,但其生产仍存在相当大的局限性。可扩展性差的制造技术和不一致的产品结构继续限制着VLPs的全部潜力。无细胞蛋白质合成(CFPS)为VLP生产提供了一种替代方法,并且已经证明是成功的,尽管使用的是来自有限数量生物体的提取物。使用最近开发的基于CFPS的系统,我们已经证明了作为概念验证的乙型肝炎核心抗原模型VLP的生产。发现在CFPS系统中产生的VLPs具有与先前产生的那些相当的特性。此外,我们已经开发了一种简便快速的合成、组装和纯化方法,可作为疫苗开发或合成生物学应用的快速原型平台。总体而言,CFPS方法允许更高的通量,这将加快对更坚固和稳定的VLPs的最佳组装条件的筛选。因此,这种方法可以支持对更大样本集的表征,以提高疫苗开发效率。